|
Orthologous residues
|
|
CCT2 (human): S260‑p, CCT2 (mouse): S260‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
mass spectrometry, mutation of modification site, phospho-antibody, western blotting
|
|
Disease tissue studied:
bone cancer
|
|
Relevant cell lines - cell types - tissues:
293 (epithelial), 293T (epithelial), HMEC (endothelial), U2OS (bone cell)
|
|
Cellular systems studied:
cell lines
|
|
Species studied:
human
|
|
Enzymes shown to modify site in vitro:
|
|
|
|
Upstream Regulation
|
|
Potential in vivo enzymes for site:
|
|
Type
|
Enzyme
|
Evidence
|
Notes
|
|
KINASE
|
Akt1 (human)
|
transfection of wild-type enzyme, phospho-motif antibody, pharmacological inhibitor of upstream enzyme
|
|
|
KINASE
|
p70S6K (human)
|
transfection of wild-type enzyme, phospho-motif antibody, siRNA inhibition of enzyme, pharmacological inhibitor of upstream enzyme
|
|
|
KINASE
|
p90RSK (human)
|
transfection of wild-type enzyme, phospho-motif antibody, pharmacological inhibitor of upstream enzyme
|
|
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
phorbol ester
|
|
|
|
increase
|
|
|
EGF
|
|
|
|
increase
|
|
|
insulin
|
|
|
|
increase
|
|
|
U0126
|
insulin
|
|
|
no effect upon treatment-induced increase
|
|
|
LY294002
|
insulin
|
|
|
inhibit treatment-induced increase
|
|
|
rapamycin
|
insulin
|
|
|
inhibit treatment-induced increase
|
|
|
siRNA
|
insulin
|
|
|
inhibit treatment-induced increase
|
|
|
|
Downstream Regulation
|
|
Effect of modification (process):
cell growth, altered
|
|
Comments:
regulates cell proliferation
|
